|
1
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bergers G and Hanahan D: Modes of
resistance to anti-angiogenic therapy. Nat Rev Cancer. 8:592–603.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Burger RA, Brady MF, Bookman MA, Fleming
GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE,
et al: Incorporation of bevacizumab in the primary treatment of
ovarian cancer. N Engl J Med. 365:2473–2483. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Perren TJ, Swart AM, Pfisterer J,
Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P,
Cervantes A, Kurzeder C, et al: A Phase 3 trial of bevacizumab in
ovarian cancer. N Engl J Med. 365:2484–2496. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bu P, Chen KY, Chen JH, Wang L, Walters J,
Shin YJ, Goerger JP, Sun J, Witherspoon M, Rakhilin N, et al: A
microRNA miR-34aregulated bimodal switch targets Notch in colon
cancer stem cells. Cell Stem Cell. 12:602–615. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Özgül Özdemir RB, Özdemir AT, Oltulu F,
Kurt K, Yiğittürk G and Kırmaz C: A comparison of cancer stem cell
markers and nonclassical major histocompatibility complex antigens
in colorectal tumor and noncancerous tissues. Ann Diagn Pathol.
25:60–63. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kreso A, O'Brien CA, van Galen P, Gan OI,
Notta F, Brown AM, Ng K, Ma J, Wienholds E, Dunant C, et al:
Variable clonal repopulation dynamics influence chemotherapy
response in colorectal cancer. Science. 339:543–548. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
de Sousa e Melo F, Kurtova AV, Harnoss JM,
Kljavin N, Hoeck JD, Hung J, Anderson JE, Storm EE, Modrusan Z,
Koeppen H, et al: A distinct role for Lgr5+ stem cells
in primary and metastatic colon cancer. Nature. 543:676–680. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cho SH, Park YS, Kim HJ, Kim CH, Lim SW,
Huh JW, Lee JH and Kim HR: CD44 enhances the epithelial-mesenchymal
transition in association with colon cancer invasion. Int J Oncol.
41:211–218. 2012.PubMed/NCBI
|
|
10
|
Prasetyanti PR, Zimberlin CD, Bots M,
Vermeulen L, Melo Fde S and Medema JP: Regulation of stem cell
self-renewal and differentiation by Wnt and Notch are conserved
throughout the adenoma-carcinoma sequence in the colon. Mol Cancer.
12:1262013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bates RC, Edwards NS, Burns GF and Fisher
DE: A CD44 survival pathway triggers chemoresistance via lyn kinase
and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer
Res. 61:5275–5283. 2001.PubMed/NCBI
|
|
12
|
Adorno-Cruz V, Kibria G, Liu X, Doherty M,
Junk DJ, Guan D, Hubert C, Venere M, Mulkearns-Hubert E, Sinyuk M,
et al: Cancer stem cells: Targeting the roots of cancer, seeds of
metastasis, and sources of therapy resistance. Cancer Res.
75:924–929. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Van der Flier LG and Clevers H: Stem
cells, self-renewal, and differentiation in the intestinal
epithelium. Annu Rev Physiol. 71:241–260. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Srinivasan T, Walters J, Bu P, Than EB,
Tung KL, Chen KY, Panarelli N, Milsom J, Augenlicht L, Lipkin SM,
et al: NOTCH signaling regulates asymmetric cell fate of Fast- and
Slow-cycling colon cancer-initiating cells. Cancer Res.
76:3411–3421. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Louvi A and Artavanis-Tsakonas S: Notch
and disease: A growing field. Semin Cell Dev Biol. 23:473–480.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bray SJ: Notch signalling: A simple
pathway becomes complex. Nat Rev Mol Cell Biol. 7:678–689. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li JL, Sainson RC, Oon CE, Turley H, Leek
R, Sheldon H, Bridges E, Shi W, Snell C, Bowden ET, et al:
DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy
in vivo. Cancer Res. 71:6073–6083. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Negri FV, Crafa P, Pedrazzi G, Bozzetti C,
Lagrasta C, Gardini G, Tamagnini I, Bisagni A, Azzoni C, Bottarelli
L, et al: Strong Notch activation hinders bevacizumab efficacy in
advanced colorectal cancer. Future Oncol. 11:3167–3174. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dalerba P, Dylla SJ, Park IK, Liu R, Wang
X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, et al:
Phenotypic characterization of human colorectal cancer stem cells.
Proc Natl Acad Sci USA. 104:10158–10163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nagano O and Saya H: Mechanismand
biological significance of CD44 cleavage. Cancer Sci. 95:930–935.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Aruffo A, Stamenkovic I, Melnick M,
Underhill CB and Seed B: CD44 is the principal cell surface
receptor for hyaluronate. Cell. 61:1303–1313. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lv L, Liu HG, Dong SY, Yang F, Wang QX,
Guo GL, Pan YF and Zhang XH: Upregulation of CD44v6 contributes to
acquired chemoresistance via the modulation of autophagy in colon
cancer SW480 cells. Tumour Biol. 37:8811–8824. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pan T, Xu J and Zhu Y: Self-renewal
molecular mechanisms of colorectal cancer stem cells. Int J Mol
Med. 39:9–20. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mousa L, Salem ME and Mikhail S:
Biomarkers of angiogenesis in colorectal cancer. Biomark Cancer. 7
(Suppl 1):S13–S19. 2015.
|
|
25
|
Sobrero A, Ackland S, Clarke S,
Perez-Carrión R, Chiara S, Gapski J, Mainwaring P, Langer B and
Young S; AVIRI Trial investigators, : Phase IV study of bevacizumab
in combination with infusional fluorouracil, leucovorin and
irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.
Oncology. 77:113–119. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cunningham D, Lang I, Marcuello E, Lorusso
V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N, Waterkamp D, et
al: Bevacizumab plus capecitabine versus capecitabine alone in
elderly patients with previously untreated metastatic colorectal
cancer (AVEX): An open-label, randomized phase 3 trial. Lancet
Oncol. 14:1077–1085. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Loupakis F, Cremolini C, Masi G, Lonardi
S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi
R, et al: Initial therapy with FOLFOXIRI and bevacizumab for
metastatic colorectal cancer. N Engl J Med. 371:1609–1618. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Passardi A, Nanni O, Tassinari D, Turci D,
Cavanna L, Fontana A, Ruscelli S, Mucciarini C, Lorusso V,
Ragazzini A, et al: Effectiveness of bevacizumab added to standard
chemotherapy in metastatic colorectal cancer: Final results for
first-line treatment from the ITACa randomized clinical trial. Ann
Oncol. 26:1201–1207. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bossi P, Viale G, Lee AK, Alfano R, Coggi
G and Bosari S: Angiogenesis in colorectal tumors: Microvessel
quantitation in adenomas and carcinomas with clinicopathological
correlations. Cancer Res. 55:5049–5053. 1995.PubMed/NCBI
|
|
31
|
Pfaffl MW, Horgan GW and Dempfle L:
Relative expression software tool (REST) for group-wise comparison
and statistical analysis of relative expression results in
real-time PCR. Nucleic Acids Res. 30:e362002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hosmer DW, Lemeshow S and May S: Applied
Survival analysis: Regression modeling of time-to-event data2nd.
John Wiley & Sons Inc.; Hoboken, NJ: 2008
|
|
33
|
Mills M: Introducing survival and Event
History analysis1st. Sage Publications Ltd.; London: 2011
|
|
34
|
Papaccio F, Paino F, Regad T, Papaccio G,
Desiderio V and Tirino V: Concise review: Cancer cells, cancer stem
cells, and mesenchymal stem cells: Influence in cancer development.
Stem Cells Transl Med. 6:2115–2125. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Blank U, Karlsson G and Karlsson S:
Signaling pathways governing stem-cell fate. Blood. 111:492–503.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang P, Lan C, Xiong S, Zhao X, Shan Y, Hu
R, Wan W, Yu S, Liao B, Li G, et al: HIF1α regulates single
differentiated glioma cell dedifferentiation to stem-like cell
phenotypes with high tumorigenic potential under hypoxia.
Oncotarget. 8:28074–28092. 2017.PubMed/NCBI
|
|
37
|
Williams K, Motiani K, Giridhar PV and
Kasper S: CD44 integrates signaling in normal stem cell, cancer
stem cell and (pre)metastatic niches. Exp Biol Med. 238:324–338.
2013. View Article : Google Scholar
|
|
38
|
Ponta H, Sherman L and Herrlich PA: CD44:
From adhesion molecules to signalling regulators. Nat Rev Mol Cell
Biol. 4:33–45. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Riccio O, van Gijn ME, Bezdek AC,
Pellegrinet L, van Es JH, Zimber-Strobl U, Strobl LJ, Honjo T,
Clevers H and Radtke F: Loss of intestinal crypt progenitor cells
owing to inactivation of both Notch1 and Notch2 is accompanied by
derepression of CDK inhibitors p27Kip1 and
p57Kip2. EMBO Rep. 9:377–383. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pellegrinet L, Rodilla V, Liu Z, Chen S,
Koch U, Espinosa L, Kaestner KH, Kopan R, Lewis J and Radtke F:
Dll1- and dll4-mediated notch signaling are required for
homeostasis of intestinal stem cells. Gastroenterology.
140:1230–1240.e1-e7. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li JL, Sainson RC, Shi W, Leek R,
Harrington LS, Preusser M, Biswas S, Turley H, Heikamp E,
Hainfellner JA, et al: Delta-like 4 Notch ligand regulates tumor
angiogenesis, improves tumor vascular function, and promotes tumor
growth in vivo. Cancer Res. 67:11244–11253. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Des Guetz G, Uzzan B, Nicolas P, Cucherat
M, Morere JF, Benamouzig R, Breau JL and Perret GY: Microvessel
density and VEGF expression are prognostic factors in colorectal
cancer. Meta-analysis of the literature. Br J Cancer. 94:1823–1832.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sundov Z, Tomic S, Alfirevic S, Sundov A,
Capkun V, Nincevic Z, Nincevic J, Kunac N, Kontic M, Poljak N and
Druzijanic N: Prognostic value of MVD, LVD and vascular invasion in
lymph node-negative colon cancer. Hepatogastroenterology.
60:432–438. 2013.PubMed/NCBI
|
|
44
|
Gao J, Knutsen A, Arbman G, Carstensen J,
Frånlund B and Sun XF: Clinical and biological significance of
angiogenesis and lymphan-giogenesis in colorectal cancer. Dig Liver
Dis. 41:116–122. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zygoń J, Szajewski M, Kruszewski WJ and
Rzepko R: VEGF, Flt-1, and microvessel density in primary tumors as
predictive factors of colorectal cancer prognosis. Mol Clin Oncol.
6:243–248. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Custodio A, Barriuso J, de Castro J,
Martínez-Marín V, Moreno V, Rodríguez-Salas N and Feliu J:
Molecular markers to predict outcome to antiangiogenic therapies in
colorectal cancer: Current evidence and future perspectives. Cancer
Treat Rev. 39:908–924. 2013. View Article : Google Scholar : PubMed/NCBI
|
